Next-Gen Antibodies —
Bi- and Multi-Specifics
Do you want to stay ahead in the discovery and development of cutting edge biotherapeutics such as bispecifics, multispecifics, and scFvs? From library design to clinical development, digitalization is the key to streamlining your entire workflow and accelerating the development of the next generation of immunotherapeutics.
This is where Genedata comes in.
Our Customers
- Digitalized Screening. Maximized Throughput.
- Centralized Data. Structured and FAIR.
- Molecular Engineering. Realized.
- Bioprocess Development. Optimized.
- Characterization Assays. Automated.
- Translational & Multiomics Insights. Unlocked.
Digitalized Screening. Maximized Throughput.
- Automate both library and large-molecule screens while maintaining complete candidate traceability.
- Screen individual binding domains or in-format multispecifics.
- Manage and track all libraries and evaluate library diversity with automated NGS data analysis.
- Use a comprehensive decision-making suite to rapidly progress candidates and have all characterization data included.
Centralized Data. Structured and FAIR.
- Derive value from your data – wherever you’re located – with a platform that facilitates FAIR principles.
- Access all discovery project information, whether you’re an engineering team designing novel binding regions for new multi-specific antibodies, or a data scientist using our advanced structured data model and extensive APIs for custom analyses and AI.
Molecular Engineering. Realized.
- Systematically and modularly design any large-molecule format without the need to copy and paste sequences. Automatically create relevant expression vectors and produce candidates for high throughput characterization with proprietary large-molecule engineering tools.
- Capture, annotate, and process all sequence information needed for engineering workflows such as in silico cloning, humanization, optimization, and conjugation, with built-in feasibility checks.
- Execute automated production and optimization workflows to rapidly develop candidates and reduce project timelines.
Bioprocess Development. Optimized.
- Develop innovative processes to manufacture next-generation antibodies faster.
- Automatically capture instrument data from bioreactors to chromatography instruments to avoid manual data transfer and ensure data integrity.
- Integrate data from CLD, USP, DSP and formulation groups, enable comprehensive analytical development, automate reporting, and reduce project timelines.
- Robustly and accurately monitor critical quality attributes (CQA) assessed by any number of process analytical technologies (PATs), mass spectrometry, or NGS.
- Implement Quality by Design (QbD) more easily thanks to end-to-end, automated data capture and systematic analysis.
Characterization Assays. Automated.
- Streamline complex analyses such as binding data analyses from surface plasmon resonance experiments or glycosylation site analysis by mass spectrometry.
- Automatically connect all your data to experimental metadata for comprehensive contextualization and better data quality.
- Access your experimental data updates across the organization in real-time, facilitating efficient expert review, error-free handover, and data science operations.
Translational & Multiomics Insights. Unlocked.
- Break down data silos and seamlessly integrate complex, multi-source data from all stages of the drug development life cycle.
- Comprehensively evaluate disease mechanisms and easily stratify patients to enroll those most likely to demonstrate therapeutic benefit.
- Identify new biomarkers by integrating clinical data with molecular, phenotypic, multiomics, real-world, and public data.
- Streamline submissions to regulatory authorities with built-in functionalities that ensure data lineage, governance, and security.
Customer Stories
High Throughput Antibody Engineering Platform
Discover how AbbVie uses Genedata Biologics to enhance antibody discovery and engineering, increasing throughput and improving data management, integration, and analysis, leading to better process efficiency and result quality.
Innovating Bispecific Antibody Development
Discover Amgen used Genedata Screener the development of bispecific antibody therapeutics, enabling them to rapidly identify, using automated analysis of high-volume data, rare bispecific molecules with promising properties for further development.